Any suspected adverse reaction to a medicinal product including those used in clinical trials should be reported via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk)
Furthermore, semaglutide prevents MASLD/MASH-driven HCC progression in metabolic preclinical models, partly by correcting adipokine imbalances (low adiponectin, high leptin) associated with insulin resistance, which removes a key chronic inflammatory and pro-oncogenic signal linked to the disease (Kojima et al., 2020)
The medication arrives in packaging that is damaged, open, labeled in a foreign language or has no expiration date
Eli Lilly needs to finish Phase 3 trials (mid-2026), submit a New Drug Application (late 2026), and wait for the FDA to review it (6 to 10 months)
With their combined expertise, Dr